UPDATE 1-FDA panel: benefit of Baxter's immune therapy outweighs risk
July 31, 2014 at 14:28 PM EDT
WASHINGTON, July 31 (Reuters) - The benefit of Baxter International Inc's experimental immune system disease therapy, HyQvia, outweigh the risks, an advisory committee to the U.S. Food and Drug Administration concluded on Thursday.
